Treats incompetent great saphenous veins, accessory saphenous veins, and visible…. Sold as Asclera, Varithena. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Polidocanol (sold as Asclera, Varithena), first approved Mar 30, 2010, with 0 new uses approved and 0 published complete response letters.
| Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and AdultsVenous Malformation, Vascular Malformations · University Hospital, Tours | Phase 3 | Not yet recruiting | Nov 12, 2026 |
| Evaluation of Polidocanol Foam Sclerotherapy in Symptomatic Internal Hemorrhoids: A Prospective StudyInternal Piles Sclerotherapy, Internal Hemorrhoids · Radwa Hussein Mohammed Hasanen | Phase 4 | Not yet recruiting | Oct 8, 2026 |
| Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and TelangiectasiasTelangiectasias, Reticular Veins · University of Sao Paulo | Phase 4 | Recruiting | Aug 28, 2026 |
| Safety and Efficacy of Microwave Ablation Alone Versus Microwave Ablation Combined With Chemical Ablation in the Treatment of Uterine Fibroids: A Prospective, Multicenter StudyUterine Fibroids (UF), Microwave Ablation · Peking University Aerospace Center Hospital | Not applicable | Not yet recruiting | Aug 10, 2026 |
| Polidocanol 1% and Steroid in Keloids and Hypertrophic ScarsKeloid and Hypertrophic Scars · Sohag University | Not applicable | Not yet recruiting | May 26, 2026 |
| Embolosclerotherapy Versus Deep Dorsal Vein Revascularization in Venogenic Erectile DysfunctionErectile Dysfunction Due to Venous Disorder, Erectile Dysfunction (ED) · Mansoura University Hospital | Not applicable | Recruiting | May 22, 2026 |
| Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous VeinVaricose Veins of Leg With Long Saphenous Vein Distribution, Varicose Veins of Lower Limb · Antonio Eduardo Zerati | Phase 4 | Recruiting | May 1, 2026 |
| Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose VeinsVaricose Veins of Lower Limb · Sir Run Run Shaw Hospital | Not applicable | Not yet recruiting | Mar 3, 2026 |
| Mar 30, 2010 | AscleraNDA 21201 · New molecular entity | Chemisch Fbrk Krsslr | 3 | Marketed |
| Nov 25, 2013 | VarithenaNDA 205098 · New formulation or manufacturer | Boston | 18 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
